Acutus Medical Suite of EP Products To Be Featured During Recorded Cases at AF Symposium 2021
January 28 2021 - 7:00AM
Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB) today announced
the presentation of two mapping and ablation procedures during the
26th Annual International AF Symposium demonstrating the beneficial
capabilities of guided ablation therapy utilizing the company’s
entire diagnostic and therapeutic suite of EP products. Prof. Tim
Betts, Oxford University Hospitals NHS Foundation Trust, Oxford,
UK, will first present a persistent atrial fibrillation procedure
using both the AcQMap 3D Imaging and Mapping System and the CE
Marked AcQBlate FORCE Sensing Ablation System1. The case will be
presented on Friday, January 29, between 11 a.m. and 1:10 p.m. ET.
On Saturday, January 30, between 10:25 a.m. and 1:00 p.m. ET,
Dr. Dhanunjaya Lakkireddy, Kansas City Heart Rhythm Institute, will
present a second procedure using Acutus Medical’s AcQMap SuperMap
software to facilitate a peer-to-peer discussion on the benefits of
a map, ablate, remap strategy when treating complex atrial
arrhythmias. Continuing its commitment to innovation, Acutus is
also featured in the “Early Stage and Emerging New Technologies and
Drugs in Cardiac EP I” session on January 29 between 2:40 p.m. and
3:40 p.m. ET, where Dr. Usman Siddiqui, Advent Health, will
demonstrate AcQCross Qx, a novel transseptal crossing technology,
compatible with multiple sheaths commonly used during
electrophysiology procedures.
“AF prevalence is increasing, and effective and efficient
treatment is necessary to meet the growing patient demand for
ablation procedures. Acutus is focused on developing and advancing
technology that makes it easier for physicians to improve outcomes
and shorten procedure times,” said Vince Burgess, CEO, Acutus
Medical. “The recent commercialization of our AcQBlate FORCE
Sensing Ablation System in Europe, together with our AcQMap System,
has proven what we always believed – a platform that focuses on
delivering personalized patient care is exactly what physicians
need. Both Prof. Betts’ and Dr. Lakkireddy’s procedures will
highlight the distinct advantages our portfolio delivers.”
The symposium, which will meet virtually this year from January
29-31, brings together over 100 leading experts in the field of
electrophysiology from across the world to educate and present the
latest clinical and technological advancements for the management
of atrial fibrillation (AF). Event registration and CME are
complimentary for this informative three-day scientific program.
Individuals are encouraged to register and virtually visit the
Acutus booth. For more information or to register for the 26th
Annual International AF Symposium, visit
https://www.afsymposium.com/.
About Acutus MedicalAcutus Medical is an
arrhythmia management company focused on improving the way cardiac
arrhythmias are diagnosed and treated. Acutus is committed to
advancing the field of electrophysiology with a unique array of
products and technologies which will enable more physicians to
treat more patients more efficiently and effectively. Through
internal product development, acquisitions and global partnerships,
Acutus has established a global sales presence delivering a broad
portfolio of highly differentiated electrophysiology products that
provide its customers with a complete solution for catheter-based
treatment of cardiac arrhythmias. Founded in 2011, Acutus is based
in Carlsbad, California.
Follow Acutus Medical on:
- Twitter: @AcutusMedical
- LinkedIn: www.linkedin.com/company/acutus-medical-inc-/
- Facebook: @AcutusMedical
US Media ContactsLevitate(260) 408-5383
acutus@levitatenow.com
- 1 The AcQBlate System, the first and only gold-tipped,
irrigated, force-sensing ablation catheter, is currently CE-marked
and commercially available only in Europe. CAUTION: The AcQBlate
Force Sensing System is limited by U.S. law to investigational
use.
Acutus Medical (NASDAQ:AFIB)
Historical Stock Chart
From Apr 2024 to May 2024
Acutus Medical (NASDAQ:AFIB)
Historical Stock Chart
From May 2023 to May 2024